• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23371 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     National Institute for Health and Care Excellence (NICE) Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. NICE technology appraisal guidance 275
2013     NIHR Health Technology Assessment programme Exercise for depression in care home residents: a randomised controlled trial with cost-effectiveness analysis (OPERA)
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety
2013     HAYES, Inc. Cold compression therapy for orthopedic conditions
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) X-ray series for foot and ankle injuries: clinical evidence, cost-effectiveness, and guidelines
2013     Malaysian Health Technology Assessment (MaHTAS) INJEX (needle free drug delivery system)
2013     National Institute for Health and Care Excellence (NICE) Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. NICE technology appraisal guidance 276
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Assessment of the PARLER (Programme d'Accès Rapide Lavallois en Rhumatologie) program]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Counselling or psychotherapy interventions for patients with a history of sexual or physical assault: patient benefits, harms, and guidelines
2013     HAYES, Inc. Endoscopic epidural adhesiolysis for chronic back pain
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Adjuvant and neoadjuvant chemotherapy and radiation for the treatment of rectal cancer: economic evidence
2013     National Institute for Health and Care Excellence (NICE) Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal). NICE technology appraisal guidance 277
2013     National Institute for Health and Care Excellence (NICE) E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta. NICE medical technologies guidance 16
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Automation for the preparation of intravenous solutions for acute care patients: cost-effectiveness and safety
2013     HAYES, Inc. Endovascular iliac atherectomy for treatment of peripheral arterial disease
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal screening procedures prior to physician visits: guidelines
2013     National Institute for Health and Care Excellence (NICE) Omalizumab for treating severe persistent allergic asthma. NICE technology appraisal guidance 278
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Sexual Assault Nurse Evaluation (SANE) rape crisis procedure: clinical effectiveness and guidelines
2013     HAYES, Inc. Epidural injection of enbrel (etanercept; Immunex Corp.) for treatment of low back pain due to lumbar disc disease
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Anaphylaxis in seniors eeceiving intravenous antibiotics in long-term care: clinical evidence and guidelines
2013     Malaysian Health Technology Assessment (MaHTAS) HAIFU® Model- Jc focused ultrasound tumor therapeutic system - an update
2013     National Institute for Health and Care Excellence (NICE) Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures. NICE technology appraisal guidance 279
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness
2013     HAYES, Inc. Galectin-3 in vitro diagnostic assay (BG Medicine Inc.) for the management of patients with chronic heart failure
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Oral lidocaine for reflux or mucositis: clinical evidence and guidelines
2013     National Institute for Health and Care Excellence (NICE) Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 283
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [The efficacy of rehabilitative interventions and pharmacological treatments for children aged 2 to 12 years with autism spectrum disorder (ASD)]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Total contact casts for diabetic foot ulcers: cost-effectiveness
2013     HAYES, Inc. Home-based cervical traction for treatment of neck pain
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Prevention and management of violence in long-term care: clinical evidence and guidelines
2013     Malaysian Health Technology Assessment (MaHTAS) EndostatTM antimicrobial treatment
2013     National Institute for Health and Care Excellence (NICE) Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. NICE technology appraisal guidance 284
2013     NIHR Health Technology Assessment programme Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Point of care testing for human chorionic gonadotropin, creatinine, and blood urea nitrogen: cost-effectiveness
2013     HAYES, Inc. Home ultraviolet B phototherapy for psoriasis
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) High-sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndrome in the emergency department
2013     National Institute for Health and Care Excellence (NICE) Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. NICE technology appraisal guidance 285
2013     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model
2013     Agency for Healthcare Research and Quality (AHRQ) Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tranexamic acid for the management of bleeding: a review of the clinical effectiveness and guidelines
2013     HAYES, Inc. Musculoskeletal ultrasonography for diagnosis of low back pain
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Components and materials used for total hip replacement: a review of the comparative clinical effectiveness
2013     National Institute for Health and Care Excellence (NICE) Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal). NICE technology appraisal guidance 286
2013     Agency for Healthcare Research and Quality (AHRQ) Evaluation and treatment of tinnitus: comparative effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures: a description of utilization trends across Canada
2013     HAYES, Inc. Outpatient cervical traction for treatment of neck pain
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Knee implant systems: a review of the comparative clinical effectiveness
2013     National Institute for Health and Care Excellence (NICE) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287
2013     Agency for Healthcare Research and Quality (AHRQ) Interventions for adult offenders with serious mental illness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence
2013     HAYES, Inc. Percutaneous epidural adhesiolysis for chronic back pain
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Intramuscular oxytocin for the prevention of post-partum hemorrhage outside the hospital: clinical evidence and guidelines
2013     National Institute for Health and Care Excellence (NICE) Dapagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 288
2013     Agency for Healthcare Research and Quality (AHRQ) Treatments for seasonal allergic rhinitis
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Antimicrobial ointments for patients undergoing hemodialysis: a review of evidence-based guidelines
2013     HAYES, Inc. Postoperative intensity-modulated radiation therapy for sinus cancers
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Warming of amniofluid: safety
2013     National Institute for Health and Care Excellence (NICE) Mirabegron for treating symptoms of overactive bladder. NICE technology appraisal guidance 290
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Advisability of expanding the Québec newborn blood screening program]
2013     Agency for Healthcare Research and Quality (AHRQ) Treatment of atrial fibrillation
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Single-use versus single patient-use electric breast pump kits for the prevention of hospital-acquired infections in mothers and newborns: comparative safety
2013     HAYES, Inc. Postoperative intra-articular viscosupplementation for treatment of knee conditions
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Point of care testing compared to laboratory testing for the assessment of white blood cell counts and differentials: a review of the clinical effectiveness, diagnostic precision and accuracy, cost-effectiveness, and guidelines
2013     National Institute for Health and Care Excellence (NICE) Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. NICE technology appraisal guidance 292
2013     Agency for Healthcare Research and Quality (AHRQ) Screening for Methicillin-Resistant Staphylococcus Aureus (MRSA)
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Management of childbirth by midwives: clinical evidence and guidelines
2013     HAYES, Inc. Radiesse voice injectable implant (Merz Aesthetics Inc.) for treatment of glottic insufficiency including vocal cord paralysis
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Frequency of blood pressure measurements for children and adults: evidence-based guidelines
2013     National Institute for Health and Care Excellence (NICE) Eltrombopag for treating chronic immune thrombocytopenia. NICE technology appraisal guidance 293
2013     Agency for Healthcare Research and Quality (AHRQ) Local nonsurgical therapies for stage 1 and symptomatic obstructive non–small-cell lung cancer
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) External devices for cervical spine immobilization in the pre-hospital setting: clinical effectiveness
2013     HAYES, Inc. Remicade (infliximab; Janssen Biotech Inc.) for first-line treatment of pediatric crohn's disease
2013     Blue Cross Blue Shield Association (BCBS) Percutaneous left atrial appendage closure therapy for the prevention of stroke
2013     National Institute for Health and Care Excellence (NICE) Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance 294
2013     Agency for Healthcare Research and Quality (AHRQ) Migraine in children: preventive pharmacologic treatments
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Removal of intravenous lines following outpatient day procedures: guidelines
2013     HAYES, Inc. Robotically assisted mitral valve repair using the da Vinci surgical system (Intuitive Surgical Inc.)
2013     National Institute for Health and Care Excellence (NICE) Ocriplasmin for treating vitreomacular traction. NICE technology appraisal guidance 297
2013     Agency for Healthcare Research and Quality (AHRQ) Migraine in adults: preventive pharmacologic treatments
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Ferumoxytol versus other intravenous iron therapies for anemia: a review of the clinical and cost-effectiveness and guidelines
2013     HAYES, Inc. S-ICD (Subcutaneous Implantable Cardioverter Defibrillator; Boston Scientific Corp.) for prevention of sudden cardiac death
2013     Blue Cross Blue Shield Association (BCBS) Noninvasive prenatal cell-free fetal DNA-based screening for aneuploidies other than trisomy 21
2013     National Institute for Health and Care Excellence (NICE) Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. NICE technology appraisal guidance 298
2013     Agency for Healthcare Research and Quality (AHRQ) Oral contraceptive use for the primary prevention of ovarian cancer
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness
2013     HAYES, Inc. Single-Incision Laparoscopic Surgery (SILS) for hysterectomy for benign disease
2013     National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. NICE technology appraisal guidance 300
2013     Agency for Healthcare Research and Quality (AHRQ) Bariatric surgery and nonsurgical therapy in adults with metabolic conditions and a body mass index of 30.0 to 34.9 kg/m2
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for chronic pain: clinical effectiveness, safety, and guidelines
2013     HAYES, Inc. Solesta (Q-Med AB) for treatment of fecal incontinence
2013     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy. NICE technology appraisal guidance 301
2013     Agency for Healthcare Research and Quality (AHRQ) Pharmacologic and mechanical prophylaxis of venous thromboembolism among special populations
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for nausea or vomiting not related to chemotherapy: clinical effectiveness and safety
2013     HAYES, Inc. Stelara (ustekinumab; Janssen Biotech Inc.) for treatment of psoriatic arthritis
2013     National Institute for Health and Care Excellence (NICE) Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal). NICE technology appraisal guidance 302
2013     Agency for Healthcare Research and Quality (AHRQ) Treatment strategies for patients with peripheral artery disease
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines
2013     HAYES, Inc. Transarterial embolization with embozene microspheres (CeloNova BioSciences Inc.) for treatment of hepatocellular carcinoma and other liver tumors
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of medullary neurostimulators for the treatment of chronic non-cancer pain]
2013     Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with melanoma yield clinical and economic benefits?